Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidn...(be created. The de-identifieddata was th...),Health

The first analysis was based on 3.4 million eGFR results in October 2006, and 2.8 million microalbumin tests between November 2005 and October 2006. The analysis determined the percentage of patients with eGFR <60 who had a microalbumin test performed during the previous 12 months, grouped by diagnosis.

The second analysis is based on approximately 13 million test results for diabetes (HbA1c), low-density lipoprotein cholesterol (LDL) and kidney disease (eGFR and microalbumin) performed in 2006, on 7.9 million unique patients. Of these test results, 500,000 met all the criteria for inclusion in the final analysis. Stage of CKD was based on patients having, on at least two occasions 90 days or more apart, an eGFR result of <60 mL/min/1.73 m or a microalbumin result >30. For patients with multiple eGFR results during a single time period, the average of the two lowest eGFR scores was used to define stage of CKD.

In both studies described above, the presence of CVD (including a subset of patients with hypertension) and diabetes were identified by specified ICD-9 diagnostic codes, which are used by the diagnostics industry to categorize diseases.

Quest Diagnostics Health Trends(TM)

Quest Diagnostics maintains the largest private clinical laboratory data warehouse in the United States. Consisting of 17 billion data points, and growing by 10 million a day, the database provides laboratory information on the vast majority of conditions and diseases affecting Americans today. Quest Diagnostics provides these data to health plans to help manage the health of their members. Quest Diagnostics Health Trends(TM) Reports identify and track disease and wellness benchmarks
'/>"/>